Cutaneous squamous cell carcinoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab monotherapy Variant #01 | — | R 286 955 | 14d | ~5.3 mo | ~32.7 mo | ~12 | ~R 3 443 463 PFS proxy · indirect | 12 |
Cetuximab monotherapy Variant #04 | — | R 29 164 | 7d | — | ~7.5 mo | — | — | 6 |
Cisplatin and Doxorubicin N/A - secondary systemic drug | — | R 3 077 | 21d | ~5.7 mo | ~12.3 mo | ~9 | ~R 27 693 PFS proxy · indirect | 4 |
Cisplatin, Interferon alfa-2a, Isotretinoin Variant #01 | — | R 350 | 7d | — | — | — | — | — |
Cemiplimab monotherapy Variant #01 Partial | — | — | 21d | ~10.3 mo | ~19.1 mo | ~15 | — | 7 |
5 of 5 regimens shown